In a new study, researchers have discovered a potential new antibody therapy for COVID-19.
The research was conducted by a team at The University of Texas.
Antibodies are proteins that allow the body to fight viruses such as SARS-CoV-2, the virus that causes COVID-19.
According to the team, antibody-based therapy is a viable drug modality for the treatment of COVID-19.
By leveraging the unique antibody-drug discovery capabilities at UTHealth, the team started to generate SARS-CoV-2-neutralizing antibodies in February of last year.
The lead antibody combination out of the research is now being developed with a biotech partner for the treatment of COVID-19.
In the study, the researchers identified a combination of two antibodies CoV2-06 and CoV2-14 that may help stop the spread of COVID-19.
They say with the onslaught of the COVID-19 crisis, it is important to develop new preventive and therapeutic methods that can offer great promise in the management of the disease.
The work was supported by grants from the Cancer Prevention and Research Institute of Texas, National Institutes of Health, Welch Foundation, Sealy Smith Foundation, Kleberg Foundation, John S. Dunn Foundation, Amon G. Carter Foundation, Gillson Longenbaugh Foundation, and the Summerfield Robert Foundation.
One author of the study is Zhiqiang An, Ph.D., professor and Robert A. Welch Distinguished University Chair in Chemistry at McGovern Medical School at UTHealth.
The study is published in Nature Communications.
Copyright © 2021 Knowridge Science Report. All rights reserved.
